One pill doesn’t cure all
Tuesday, May 8th, 2012The makers of an epilepsy drug that was later marketed as a treatment for schizophrenia as well as dementia-related agitation must pay $1.5 billion to settle a mass of lawsuits. The claims allege that Abbott Laboratories, producers of Depakote, pushed for sales of the drug to treat schizophrenia and dementia-related agitation, even though the drug was not approved for such treatment, nor was there any scientific evidence to support use of the drug for those conditions.




